BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 10834311)

  • 1. Effective priming of cytotoxic T lymphocyte precursors by subcutaneous administration of peptide antigens in liposomes accompanied by anti-CD40 and anti-CTLA-4 antibodies.
    Ito D; Ogasawara K; Matsushita K; Morohashi T; Namba K; Matsuki N; Kitaichi N; Inuyama Y; Hosokawa M; Nakayama E; Iwabuchi K; Onoé K
    Immunobiology; 2000 Apr; 201(5):527-40. PubMed ID: 10834311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of CTL responses by simultaneous administration of liposomal peptide vaccine with anti-CD40 and anti-CTLA-4 mAb.
    Ito D; Ogasawara K; Iwabuchi K; Inuyama Y; Onoé K
    J Immunol; 2000 Feb; 164(3):1230-5. PubMed ID: 10640735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CTLA-4 (CD152) inhibits the specific lysis mediated by human cytolytic T lymphocytes in a clonally distributed fashion.
    Saverino D; Tenca C; Zarcone D; Merlo A; Megiovanni AM; Valle MT; Manca F; Grossi CE; Ciccone E
    J Immunol; 1999 Jan; 162(2):651-8. PubMed ID: 9916682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
    Davila E; Kennedy R; Celis E
    Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blockade of CD40 pathway enhances the induction of immune tolerance by immature dendritic cells genetically modified to express cytotoxic T lymphocyte antigen 4 immunoglobulin.
    Sun W; Wang Q; Zhang L; Liu Y; Zhang M; Wang C; Wang J; Cao X
    Transplantation; 2003 Nov; 76(9):1351-9. PubMed ID: 14627915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD28 ligation by monoclonal antibodies or B7/BB1 provides an accessory signal for the cyclosporin A-resistant generation of cytotoxic T cell activity.
    Van Gool SW; de Boer M; Ceuppens JL
    J Immunol; 1993 Apr; 150(8 Pt 1):3254-63. PubMed ID: 7682237
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Partial activation of naive CD4 T cells and tolerance induction in response to peptide presented by resting B cells.
    Croft M; Joseph SB; Miner KT
    J Immunol; 1997 Oct; 159(7):3257-65. PubMed ID: 9317124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. B7-1 but not B7-2 efficiently costimulates CD8+ T lymphocytes in the P815 tumor system in vitro.
    Gajewski TF
    J Immunol; 1996 Jan; 156(2):465-72. PubMed ID: 8543795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) can regulate dendritic cell-induced activation and cytotoxicity of CD8(+) T cells independently of CD4(+) T cell help.
    McCoy KD; Hermans IF; Fraser JH; Le Gros G; Ronchese F
    J Exp Med; 1999 Apr; 189(7):1157-62. PubMed ID: 10190907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: the effect is manifested only at the restricted tumor-bearing stages.
    Yang YF; Zou JP; Mu J; Wijesuriya R; Ono S; Walunas T; Bluestone J; Fujiwara H; Hamaoka T
    Cancer Res; 1997 Sep; 57(18):4036-41. PubMed ID: 9307290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human dendritic cells activate T lymphocytes via a CD40: CD40 ligand-dependent pathway.
    McLellan AD; Sorg RV; Williams LA; Hart DN
    Eur J Immunol; 1996 Jun; 26(6):1204-10. PubMed ID: 8647193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antigen-dependent clonal expansion of a trace population of antigen-specific CD4+ T cells in vivo is dependent on CD28 costimulation and inhibited by CTLA-4.
    Kearney ER; Walunas TL; Karr RW; Morton PA; Loh DY; Bluestone JA; Jenkins MK
    J Immunol; 1995 Aug; 155(3):1032-6. PubMed ID: 7543510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IFN-gamma is critical for long-term allograft survival induced by blocking the CD28 and CD40 ligand T cell costimulation pathways.
    Konieczny BT; Dai Z; Elwood ET; Saleem S; Linsley PS; Baddoura FK; Larsen CP; Pearson TC; Lakkis FG
    J Immunol; 1998 Mar; 160(5):2059-64. PubMed ID: 9498741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination therapy of established tumors by antibodies targeting immune activating and suppressing molecules.
    Takeda K; Kojima Y; Uno T; Hayakawa Y; Teng MW; Yoshizawa H; Yagita H; Gejyo F; Okumura K; Smyth MJ
    J Immunol; 2010 May; 184(10):5493-501. PubMed ID: 20400706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Local activation of CD8 T cells and systemic tumor eradication without toxicity via slow release and local delivery of agonistic CD40 antibody.
    Fransen MF; Sluijter M; Morreau H; Arens R; Melief CJ
    Clin Cancer Res; 2011 Apr; 17(8):2270-80. PubMed ID: 21389097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Opposing roles of CD28:B7 and CTLA-4:B7 pathways in regulating in vivo alloresponses in murine recipients of MHC disparate T cells.
    Blazar BR; Taylor PA; Panoskaltsis-Mortari A; Sharpe AH; Vallera DA
    J Immunol; 1999 Jun; 162(11):6368-77. PubMed ID: 10352249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals.
    Mitsui J; Nishikawa H; Muraoka D; Wang L; Noguchi T; Sato E; Kondo S; Allison JP; Sakaguchi S; Old LJ; Kato T; Shiku H
    Clin Cancer Res; 2010 May; 16(10):2781-91. PubMed ID: 20460483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CTLA-4 blockade by a human MAb enhances the capacity of AML-derived DC to induce T-cell responses against AML cells in an autologous culture system.
    Zhong RK; Loken M; Lane TA; Ball ED
    Cytotherapy; 2006; 8(1):3-12. PubMed ID: 16627340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blockade of CTLA-4 enhances host resistance to the intracellular pathogen, Leishmania donovani.
    Murphy ML; Cotterell SE; Gorak PM; Engwerda CR; Kaye PM
    J Immunol; 1998 Oct; 161(8):4153-60. PubMed ID: 9780188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclophosphamide inhibition of anti-CD40 monoclonal antibody-based therapy of B cell lymphoma is dependent on CD11b+ cells.
    Honeychurch J; Glennie MJ; Illidge TM
    Cancer Res; 2005 Aug; 65(16):7493-501. PubMed ID: 16103104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.